Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of nebulized amikacin via PDDS in ventilator-associated pneumonia
2005-000060-16Phase 2Completed
- Sponsor
- Aerogen
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amikacin in ventilator-associated pneumonia (VAP) (2 arms), sponsored by Aerogen. Primary endpoint: Primary pharmacokinetic target attainment endpoint. Started Apr 2006; status: completed.
02
Drugs
amikacin
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on 2005-000060-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000060-16.